1. Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
- Author
-
Sampsa Hautaniemi, Jan Delabie, Alejandra Cervera, Amjad Alkodsi, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg, Riku Louhimo, Rainer Lehtonen, Matias Autio, Minna Taskinen, Annika Pasanen, Sirpa Leppä, Harald Holte, Ville Rantanen, Research Programs Unit, University of Helsinki, Genome-Scale Biology (GSB) Research Program, Clinicum, Department of Oncology, Sampsa Hautaniemi / Principal Investigator, Medicum, Department of Pathology, Bioinformatics, Sirpa Marianne Leppä / Principal Investigator, and HUS Comprehensive Cancer Center
- Subjects
0301 basic medicine ,Adult ,Male ,Pathology ,medicine.medical_specialty ,Anthracycline ,Ubiquitin-Protein Ligases ,education ,3122 Cancers ,DNA Mutational Analysis ,Biology ,medicine.disease_cause ,ACTIVATION ,03 medical and health sciences ,Exon ,Protein Domains ,immune system diseases ,Chemoimmunotherapy ,TARGETS ,hemic and lymphatic diseases ,medicine ,Biomarkers, Tumor ,Humans ,Online Only Articles ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Mutation ,Proportional hazards model ,fungi ,food and beverages ,Hematology ,Exons ,DEGRADATION ,Middle Aged ,medicine.disease ,Prognosis ,3. Good health ,Lymphoma ,Gene expression profiling ,GENOME ,030104 developmental biology ,Cancer research ,Female ,Lymphoma, Large B-Cell, Diffuse ,Neoplasm Grading ,Diffuse large B-cell lymphoma ,SUSTAINS - Abstract
Diffuse large B-cell lymphoma (DLBCL) is a group of clinically aggressive and heterogeneous malignancies, of which approximately 60% can be cured with anthracycline-based chemoimmunotherapy. Based on gene expression profiling, DLBCL can be classified into two molecularly distinct subgroups showing
- Published
- 2017